ClinicalTrials.gov
public full text
Public Domain
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients. The patients in this study will be treated with the study medicine imlifidase on day 1, and with IVIg on days 3-7. The purpose of this study is to investigate the safety and effectiveness of imlifidase in patients diagnosed with GBS.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines#4575
- Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins#884910
- Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody–mediated diseases: post hoc analyses of 3 randomized, placebo-controlled trials#236473
- A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies#1151220
- Azathioprine in MOGAD#1170822
Record · ID 843018
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive